Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma

This publication has 10 references indexed in Scilit:

• Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
  Blood, 2014
• B Cell Depletion Curtails CD4+ T Cell Memory and Reduces Protection against Disseminating Virus Infection
  The Journal of Immunology, 2014
• Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre
  Rheumatology, 2013
• Rituximab‐Induced T Cell Depletion in Patients With Rheumatoid Arthritis: Association With Clinical Response
  Arthritis & Rheumatism, 2013
• Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  Journal of Clinical Oncology, 2013
• Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
  Cancer Chemotherapy and Pharmacology, 2013
• Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma
  Leukemia Research, 2011
• Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine
  Annals of Hematology, 2011
• Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel
  Clinical Lymphoma Myeloma and Leukemia, 2010
• Revised Response Criteria for Malignant Lymphoma
  Journal of Clinical Oncology, 2007